Indication

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia... Read More
Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

On-body Injector Patient Instructions for Use:

Which version of the Instructions for Use did your doctors's office give you?

If you don’t recognize the images above or if you prefer a physical copy, contact your doctor.

Onpro® Kit HCP Instructions for Use:

Which version of the HCP Instructions for Use came with your patient's on-body injector?

Frequency and cost of FN hospitalizations

200K patients icon

Nearly 200,000 hospitalizations were caused by FN in just one year1,*

According to recent estimates, each FN event costs $46,793 (on average), including hospitalization and discharge treatment2,†

*Based on a retrospective database analysis analyzing inpatient hospitalization discharges from 2016 to 2018. The primary objective was to estimate the total number of FN-related hospitalizations among adult patients in the United States during the years 2016, 2017, and 2018 using hospitalization discharge data from the National Inpatient Sample (NIS). The NIS is the largest publicly available all-payer inpatient healthcare database designed to produce US regional and national estimates of inpatient utilization, access, charges, quality, and outcomes. Unweighted, it contains data from more than 7 million hospital stays each year. Weighted, it estimates more than 35 million hospitalizations nationally. FN was defined as a hospitalized patient discharge record with: a cancer diagnosis code and a neutropenia diagnosis code and a (fever or infection) diagnosis code.1

Total costs of $46,793 per FN event per patient were calculated using estimates that included the proportion of patients that survived, died, were readmitted for any cause, were readmitted with FN and survived, and were readmitted with FN and died. Cost of an average FN hospitalization stay based on multiple data sources. It was assumed that a patient not discharged to a skilled nursing facility (SNF) incurred outpatient management costs. A factor of 1.31806 was used to estimate post-discharge non-SNF outpatient neutropenia healthcare costs. The proportion of patients who died or were readmitted was estimated using Dulisse et al, 2013. Inflation adjustment from annual 2012 to Q1 2020 for the index hospitalization, annual 2016 to Q1 2020 for the SNF stay, and annual 2010 to Q1 2020 for all-cause readmission and mortality cost used medical care consumer price indices from the Bureau of Labor Statistics.2

Evaluating FN risk

Current guidelines recommend assessing risk of FN before every cycle3

According to the American Society of Clinical Oncology (ASCO®) and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Evaluate the risk of FN and administer primary G-CSF prophylaxis in first and subsequent cycles for patients at high or intermediate FN risk.3,4

When assessing risk, evaluate both chemotherapy regimen and patient risk factors3

Chemotherapy regimen risk

Patient risk factors

According to the American Society of Clinical Oncology (ASCO®) and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Evaluate the risk of FN and administer primary CSF prophylaxis in first and subsequent cycles for patients at > 20% risk3,4

Select chemotherapy regimens associated with a

HIGH RISK OF FN

Breast cancer

  • TAC (docetaxel + doxorubicin + cyclophosphamide) Q3W3,5,*
  • TC (docetaxel + cyclophosphamide) Q3W3,6,*
  • TCH* ± P (docetaxel + carboplatin + trastuzumab with or without pertuzumab)3,7,8

Non-Hodgkin's lymphoma

  • BR (bendamustine + rituximab)9,†
  • CHOP*,‡ ± R (cyclophosphamide + doxorubicin + vincristine + prednisolone with or without rituximab) Q3W 3,10,11

Non-small cell lung cancer

  • Carboplatin + paclitaxel Q3W12,‡

Small cell lung cancer

  • Topotecan3,*

Select chemotherapy regimens associated with an

INTERMEDIATE RISK OF FN

Breast cancer

  • AC (doxorubicin + cyclophosphamide) + sequential docetaxel13,†

Non-small cell lung cancer

  • Cisplatin + etoposide3,*
  • Cisplatin + docetaxel3,14,*
  • Carboplatin + docetaxel15,†

Prostate cancer

  • Cabazitaxel3,*
  • Docetaxel + prednisone16,†

Small cell lung cancer

  • Carboplatin + etoposide3,*

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Do not administer Neulasta® between 14 days before and 24 hours after administration of chemotherapy. The recommended dosage of Neulasta® is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle.

*Select regimens listed from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and scientific publications. Please see references for source information.

Select regimens not listed by the NCCN.

Select regimens listed by the NCCN as intermediate risk. Regimens listed as high risk based on published literature showing risk of FN of 17% or greater.17

CSF = colony-stimulating factor; FN = febrile neutropenia; NCCN = National Comprehensive Cancer Network; Q3W = once every 3 weeks.

Patient-related risk factors

Icon: more than 1 risk factor

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): If your patient is on an intermediate-risk regimen and has 1 or more risk factors, consider pegfilgrastim (Neulasta® or Neulasta® Onpro®)3

Even one of these select risk factors can increase risk:3,*

Baseline cytopenias18,19

Poor performance status (ECOG ≥ 2)20

Age ≥ 65 years19

COPD21,

Chronic immunosuppression in the post-transplant
setting, including organ transplant18

Liver disease22

Renal disease19

Cardiovascular disease19,

Diabetes23,

Prior chemotherapy24

Prior radiotherapy18

Poor nutritional status25,

Decreased serum albumin25,

Open wounds/recent surgery26

Active infections27,

HIV22

Metastatic20,

Elevated lactate dehydrogenase25,

*The patient risk factors included here have been identified through published literature and clinical guidelines. This list is not exhaustive. There may be other risk factors that apply based on available research and the clinical judgment of the treating physicians. These risk factors in addition to high or intermediate risk chemotherapy regimens can increase the risk of infection.

Risk factors not listed by the NCCN.

NCCN = National Comprehensive Cancer Network; ECOG = Eastern Cooperative Oncology Group; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus.

Reducing FN risk with Neulasta®

Next-day Neulasta® reduced the incidence of FN and FN-related hospitalization when used at every cycle, at the right time17

Graph: percent of patients with FN and FN-related hospitalization

Phase 3, multicenter, multinational, double-blind, placebo-controlled trial of patients with breast cancer (Neulasta® [n = 463] or placebo [n = 465]) receiving 100mg/m2 docetaxel Q3W for up to 4 cycles. The key endpoint was the percentage of patients who developed FN (Neulasta® 1% vs placebo 17%, P < 0.001). Also, secondary endpoints were lower for Neulasta®-treated patients as compared to placebo-treated patients (the incidence of hospitalization [1% vs 14%] and IV anti-infective use [2% vs 10%]).17

FN = temperature ≥ 38.2°C and absolute neutrophil count < 0.5 x 109/L.

G-CSF = granulocyte colony-stimulating factor; Q3W = once every 3 weeks; IV = intravenous.

To help overcome next-day G-CSF delivery challenges, choose Neulasta® Onpro®

Returning to the doctor's office the day after chemotherapy can be challenging for patients

Transportation icon

Struggle to get transportation

No caregiver* and can't get back to the healthcare facility

Exposure icon

Exposure to viruses

Immunosuppressed patients may want to stay away from those with a viral infection28

Scheduling icon

Scheduling conflicts

Family or work conflicts

Holiday schedule icon

Holiday

Chemo a day before holiday closings

Weather conditions icon

Weather conditions

Such as a blizzard, could make driving hazardous

Clinic icon

Friday chemo

And the clinic is closed on Saturday

Chemotherapy icon

Multiple consecutive days of chemo

Chemo two days in a row and the patient doesn't want to come back a third day every cycle

Syringe icon

Non-compliant

Missed prefilled syringe appointment last cycle and/or didn't receive injection next day

Time icon

Live far away

Total time spent includes more than just driving time

Onpro® is the only G-CSF delivery method designed to automatically deliver Neulasta® at the right time29,†

Neulasta® Onpro® may be appropriate for all of your patients who:
  • Are adults
  • Are comfortable following the Patient Instructions for Use
  • Do not have allergies to acrylics

*For patients with Onpro® applied on the abdomen. The back of the arm may only be used if there is a caregiver available to monitor the status of the on-body injector for Neulasta®.

Incomplete doses have been reported with Neulasta® Onpro® due to device not performing as intended. This may increase risk of neutropenia, FN, and/or infection.

In a real-world study, fewer patients experienced FN with Neulasta® Onpro® vs other FN-prophylaxis options.
Explore results

Assess your patients' risk of febrile neutropenia (FN) every cycle

already-using-onpro-png

Download a risk assessment tool (as PDF or Word document) (versions are identical in content).


already-using-onpro-png

Populate checklist, including the appropriate ICD-10 codes (code descriptions are on page 2 of the checklist).

ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th Revision.


already-using-onpro-png

Saving the completed checklist to your patient's file can help facilitate prior authorization discussions with payers.

Important Safety Information

Contraindication

  • Neulasta® (pegfilgrastim) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim
  • Reactions have included anaphylaxis

Splenic Rupture

  • Splenic rupture, including fatal cases, can occur following the administration of Neulasta®
  • Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

  • ARDS has occurred in patients receiving Neulasta®
  • Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta®
  • Discontinue Neulasta® in patients with ARDS

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta®
  • Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
  • Permanently discontinue Neulasta® in patients with serious allergic reactions

Allergies to Acrylics

  • On-body injector (OBI) for Neulasta® uses acrylic adhesives
  • Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients With Sickle Cell Disorders

  • In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving Neulasta®
  • Discontinue Neulasta® if sickle cell crisis occurs

Glomerulonephritis

  • Has occurred in patients receiving Neulasta®
  • Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
  • Generally events resolved after dose reduction or discontinuation of Neulasta®
  • If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta®

Leukocytosis

  • Increased white blood cell counts of 100 x 109/L have been observed
  • Monitoring of complete blood count (CBC) during pegfilgrastim therapy is recommended

Thrombocytopenia

  • Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts

Capillary Leak Syndrome (CLS)

  • CLS has been reported after G-CSF administration, including Neulasta®
  • Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
  • Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

  • G-CSF receptor has been found on tumor cell lines
  • The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which Neulasta® is not approved, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients With Breast and Lung Cancer

  • MDS and AML have been associated with the use of Neulasta® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings

Potential Device Failures

  • Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
  • In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
  • Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

  • Aortitis has been reported in patients receiving Neulasta®. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® if aortitis is suspected

Nuclear Imaging

  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most common adverse reactions

  • Bone pain
  • Pain in extremity

Please see Neulasta® full Prescribing Information.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient’s skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient’s skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.

Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852). 1-844-MYNEULASTA (1-844-696-3852).

References:
1. Yang BB, et al. Cancer Chemother Pharmacol. 2015;75:1199-1206. 2. Neulasta® (pegfilgrastim) Prescribing Information, Amgen. 3. Kirshner JJ, et al. Support Care Cancer. 2018;26:1323-1334. 4. Yang BB, et al. Clin Pharmacokinet. 2011;50:295-306. 5. Haegerstam GA. Acta Orthop Scand. 2001;72:308-317. 6. Schweizerhof M, et al. Nat Med. 2009;15:802-807.

References:
1. Data on file, Amgen; 2021. 2. Data on file, Amgen; 2020. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 25, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Smith TJ, et al. J Clin Oncol. 2015;33:3199-3212. 5. Martin M, et al. N Engl J Med. 2005;352:2302-2313. 6. Younis T, et al. Support Care Cancer. 2012;20:2523-2530. 7. Perjeta (pertuzumab) Prescribing Information, Genentech, Inc. 8. Schneeweiss A, et al. Ann Oncol. 2013;24:2278-2284. 9. Cerchione C, et al. Support Care Cancer. 2017;25:839-845. 10. Ösby E, et al. Blood. 2003;101:3840-3848. 11. Delarue R, et al. Lancet Oncol. 2013;14:525-533. 12. Ohe Y, et al. Ann Oncol. 2007;18:317-323. 13. Swain SM, et al. N Engl J Med. 2010;362:2053-2065. 14. Schiller JH, et al. N Engl J Med. 2002;346:92-98. 15. Yoshimura N, et al. J Thorac Oncol. 2009;4:371-375. 16. Kongsted P, et al. Urol Oncol. 2015;33:494.e15-494.e20. doi:10.1016/j.urolonc.2015.06.022. 17. Vogel CL, et al. J Clin Oncol. 2005;23:1178-1184. 18. Moreau M, et al. Ann Oncol. 2009;20:513-519. 19. Lyman GH, et al. Leuk Lymphoma. 2003;44:2069-2076. 20. Lyman GH, et al. J Clin Oncol. 2004;22:4302-4311. 21. Klastersky J, et al. J Clin Oncol. 2000;18:3038-3051. 22. Chao C, et al. Ann Oncol. 2014;25:1821-1829. 23. Takenaka Y, et al. Support Care Cancer. 2013;21:2861-2868. 24. Shayne M, et al. Cancer. 2007;110:1611-1620. 25. Intragumtornchai T, et al. Leuk Lymphoma. 2000;37:351-360. 26. Family L, et al. J Clin Oncol. 2016;34. Abstract 6559. 27. Pettengell R, et al. Br J Haematol. 2008;144:677-685. 28. American Cancer Society. Watching for and Preventing Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/preventing-infections-in-people-with-cancer.html. Accessed December 20, 2021. 29. Neulasta® (pegfilgrastim) Prescribing Information, Amgen.

References:
1. Data on file, Amgen; 2021. 2. Mahtani RL, et al. A multicenter, prospective, observational study to determine the incidence of febrile neutropenia (FN), persistence and G-CSF utilization among cancer patients at high risk for FN receiving pegfilgrastim by an on-body injector (OBI) versus other FN-prophylaxis strategies. Poster presented at: San Antonio Breast Cancer Symposium®, Virtual. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 5, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Data on file, Amgen; 2020. 5. Lyman GH. J Natl Comr Canc Netw. 2009;7:2612-2615.

Reference:
1. Data on file, Amgen; 2021.

References:
1. Data on file, Amgen; [1]; 2020. 2. Data on file, Amgen; [2]; 2020. 3. Data on file, Amgen; [3]; 2020. 4. Data on file, Amgen; 2016. 5. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.

Reference:
1. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.

Important Safety Information

Contraindication

  • Neulasta® (pegfilgrastim) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim
  • Reactions have included anaphylaxis

Splenic Rupture

  • Splenic rupture, including fatal cases, can occur following the administration of Neulasta®
  • Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

  • ARDS has occurred in patients receiving Neulasta®
  • Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta®
  • Discontinue Neulasta® in patients with ARDS

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta®
  • Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
  • Permanently discontinue Neulasta® in patients with serious allergic reactions

Allergies to Acrylics

  • On-body injector (OBI) for Neulasta® uses acrylic adhesives
  • Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients With Sickle Cell Disorders

  • In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving Neulasta®
  • Discontinue Neulasta® if sickle cell crisis occurs

Glomerulonephritis

  • Has occurred in patients receiving Neulasta®
  • Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
  • Generally events resolved after dose reduction or discontinuation of Neulasta®
  • If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta®

Leukocytosis

  • Increased white blood cell counts of 100 x 109/L have been observed
  • Monitoring of complete blood count (CBC) during pegfilgrastim therapy is recommended

Thrombocytopenia

  • Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts

Capillary Leak Syndrome (CLS)

  • CLS has been reported after G-CSF administration, including Neulasta®
  • Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
  • Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

  • G-CSF receptor has been found on tumor cell lines
  • The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which Neulasta® is not approved, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients With Breast and Lung Cancer

  • MDS and AML have been associated with the use of Neulasta® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings

Potential Device Failures

  • Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
  • In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
  • Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

  • Aortitis has been reported in patients receiving Neulasta®. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® if aortitis is suspected

Nuclear Imaging

  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most common adverse reactions

  • Bone pain
  • Pain in extremity

Please see Neulasta® full Prescribing Information.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient’s skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient’s skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.

Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852). 1-844-MYNEULASTA (1-844-696-3852).